Home › Peptides A to Z › SemaglutideSemaglutide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
649 registered trials · 499 indexed papers · 3110 human / 545 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is Semaglutide is described as the active ingredient in several prescription medicines, not one interchangeable product. It belongs to the GLP-1 receptor agonist class.
Depending on the brand and formulation, approved uses are described as including type 2 diabetes, weight management and certain cardiovascular, kidney or liver conditions. Matching the specific label to the person and condition is described as what matters.
Mechanism (as described) Helps the pancreas release insulin when blood glucose is elevated, slows stomach emptying and can reduce appetite. Those effects help explain its use in diabetes and weight management. They are described as not meaning that every semaglutide product has the same approved purpose. Registered human trials (649) Peer-reviewed studies (499) Paper Authors Journal Year Type Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease Gong C et al. Medicine 2026 Observational Study Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome Ahmed S et al. Frontiers in endocrinology 2026 Observational Study Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study Giraldi LV et al. BMJ open 2026 Clinical Study Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study Tournayre S et al. Journal of medical Internet research 2026 Observational Study Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial Gullaksen S et al. Journal of diabetes and its complications 2026 Randomized Controlled Trial Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study Montaser E et al. Diabetes, obesity & metabolism 2026 Randomized Controlled Trial Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis Plutzky J et al. Circulation 2026 Randomized Controlled Trial Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial Miyake T et al. Diabetes, obesity & metabolism 2026 Randomized Controlled Trial Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial Ji L et al. The lancet. Diabetes & endocrinology 2026 Randomized Controlled Trial Obesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2) Clemens KK et al. BMJ open 2026 Clinical Study Efficacy and safety of once-weekly semaglutide 2·[amount hidden] in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial Guo L et al. The lancet. Diabetes & endocrinology 2026 Randomized Controlled Trial Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis Mann JFE et al. The lancet. Diabetes & endocrinology 2026 Randomized Controlled Trial Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials Ji L et al. Diabetes, obesity & metabolism 2026 Randomized Controlled Trial Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide Al Ozairi E et al. Diabetes/metabolism research and reviews 2026 Observational Study Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice Sawada M et al. Endocrinology, diabetes & metabolism 2026 Observational Study Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital Jha AK et al. The Journal of the Association of Physicians of India 2026 Observational Study Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study AlTaweel MO et al. Expert review of cardiovascular therapy 2026 Observational Study Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial Schacht JP et al. The American journal of psychiatry 2026 Randomized Controlled Trial Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study Lake JE et al. HIV medicine 2026 Clinical Trial, Phase II Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol Yevusiak T et al. PloS one 2026 Clinical Study Efficacy and Safety of Once-Weekly Semaglutide [amount hidden] as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE) Rodbard HW et al. Diabetes, obesity & metabolism 2026 Randomized Controlled Trial Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1 Busetto L et al. Diabetes, obesity & metabolism 2026 Randomized Controlled Trial Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study Wei Y et al. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2026 Observational Study Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial Vanlaer Y et al. BMJ open 2026 Clinical Study Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial Timmons JG et al. Diabetes, obesity & metabolism 2026 Randomized Controlled Trial Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial Loomba R et al. The lancet. Gastroenterology & hepatology 2026 Randomized Controlled Trial Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study Bach P et al. The lancet. Psychiatry 2026 Observational Study Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial Kitamoto T et al. Current medical research and opinion 2026 Randomized Controlled Trial Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes Skandov MD et al. Diabetes, obesity & metabolism 2026 Observational Study Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss Rahman E et al. Aesthetic plastic surgery 2026 Randomized Controlled Trial
More cited research 1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study (2026, human observational)Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alz (2026, human RCT)Cagrilintide-semaglutide: a new option for patients with type 2 diabetes (2026, human observational)Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice (2026, human RCT)A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-ed (2026, animal)Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice (2026, animal)Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice (2026, animal)Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison (2026, animal)Conditions researched Delayed gastric emptying on GLP-1 medicines Dementia, Alzheimer's & cognitive decline Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers Anti-aging & longevity Atherosclerosis, cardiovascular disease & high blood pressure Autism support Chronic and systemic inflammation Cognition, focus & brain performance Concussion, traumatic brain injury & stroke recovery Diabetic retinopathy and glaucoma Eyes: macular degeneration & retinal health Fat loss, obesity & body recomposition Fatty liver & elevated liver enzymes Female fertility Heart repair: after heart attack, heart failure & enlarged heart High cholesterol and statins Immune system (general) Insulin resistance, prediabetes & type 2 diabetes Kidney protection (CKD, diabetic kidney, lupus kidney) Loose skin Low testosterone (without or alongside TRT) Lung health, asthma & COPD Male fertility and sperm Menopause & perimenopause Muscle gain, sarcopenia & building muscle after 40 Muscle disease (myopathy) Neuropathy and CRPS Osteoarthritis, cartilage loss & avoiding joint replacement Osteoporosis and bone density Pancreatitis (after the acute phase) Parkinson's disease PCOS Post-surgical inflammation and surgery recovery Psoriasis and psoriatic arthritis Skin, hair loss, wounds & mast-cell/histamine reactivity Sleep apnea (obstructive) Sleep problems (incl. insomnia on peptides) Thick blood and blood clots Related compounds FAQ What is Semaglutide? The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
How many registered human trials study Semaglutide? The PeptideWhiz trial index lists 649 registered trials for Semaglutide, the most recent from 2028.
How much published research exists on Semaglutide? The PeptideWhiz paper index links 499 PubMed papers to Semaglutide; by study type, 3110 human and 545 animal studies.
Which conditions is Semaglutide researched for? Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Anti-aging & longevity, Atherosclerosis, cardiovascular disease & high blood pressure, Autism support, Chronic and systemic inflammation, Cognition, focus & brain performance, Concussion, traumatic brain injury & stroke recovery, Diabetic retinopathy and glaucoma, Eyes: macular degeneration & retinal health, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Female fertility, Heart repair: after heart attack, heart failure & enlarged heart, High cholesterol and statins, Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Loose skin, Low testosterone (without or alongside TRT), Lung health, asthma & COPD, Male fertility and sperm, Menopause & perimenopause, Muscle gain, sarcopenia & building muscle after 40, Muscle disease (myopathy), Neuropathy and CRPS, Osteoarthritis, cartilage loss & avoiding joint replacement, Osteoporosis and bone density, Pancreatitis (after the acute phase), Parkinson's disease, PCOS, Post-surgical inflammation and surgery recovery, Psoriasis and psoriatic arthritis, Skin, hair loss, wounds & mast-cell/histamine reactivity, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides), Thick blood and blood clots.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).
Reported dosing ranges from research